Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Purpose: To determine how concomitant use of potentially interacting drugs, drug dosage, and duration of therapy modify the risk of hip fracture associated with use of benzodiazepines and benzodiazepine‐related drugs (BDZ) in older adults. Methods: A nested case–control study was conducted in Medicare patients 65 years or older, enrolled in the Pennsylvania drug assistance program (PACE) between 1994 and 2005. We included 17 198 patients with a hip fracture leading to hospitalization and 85 990 controls matched on hospitalization (index date). BDZ and interacting drug use within 2 weeks preceding the index date was determined using information on date of drug dispensing, days supplied, quantity dispensed, and strength. Date of the first BDZ prescription within the year preceding the index date was used as surrogate for duration of therapy. Results: While the adjusted relative risk (RR) for overall BDZ use and hip fracture was 1.2 (95% confidence interval 1.1, 1.2), the RRs for concomitant use of alprazolam, lorazepam, and zolpidem and their interacting drugs were 1.5 (1.3, 1.7), 1.9 (1.7, 2.2), and 1.7 (1.4, 2.0), and 2.1 (1.5, 2.8) for BDZ use initiated within 14 days preceding the index date. RR increased with increasing BDZ dose and was highest for defined daily BDZ doses >1 [RR: 1.3 (1.2, 1.5)]. Conclusions: BDZ associated hip fracture risk increases with concomitant use of interacting drugs, higher doses, and is highest at initiation. Clinicians should avoid concomitant use of BDZ and interacting drugs, because their impact on hip fracture risk is at least additive. Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fick, D. M., Cooper, J. W., Wade, W. E., Waller, J. L., Maclean, J. R., & Beers, M. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.22.2716 · Cited by 2,389
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Wang, P. S., Bohn, R. L., Glynn, R. J., Mogun, H., & Avorn, J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.892 · Cited by 312
Self-citationAllain, H., Bentu??-Ferrer, D., Polard, E., Akwa, Y., & Patat, A. (2005) · Drugs & Aging · doi:10.2165/00002512-200522090-00004 · Cited by 214 · cited 1×
“In agreement with earlier studies(7,8,14) a grace period after the calculated end of supply was chosen because some BDZ have increased half-lives in the elderly or active metabolites exceeding the half-life of the BDZ by far.(10,15) BDZ users were further classified with respect to BDZ half-life, prescribed dose, and…”
MethodPsychotropic Medications and the Risk of Fracture: A Meta-Analysis
Takkouche, B., Montes-Mart??nez, A., Gill, S. S., & Etminan, M. (2007) · Drug Safety · doi:10.2165/00002018-200730020-00006 · Cited by 204 · cited 1×
“The association between benzodiazepine use in older adults and the risk of hip fracture is well established.(1,2) However, the risk of hip fracture is likely to be heterogeneous in this population.”
BackgroundBenzodiazepines with different half-life and falling in a hospitalized population
Passaro, A., Volpato, S., Romagnoni, F., Manzoli, N., Zuliani, G., & Fellin, R. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00254-7 · Cited by 122
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Psychotropic medications have been associated with an increased risk of fractures [1369,1373,1374].”
BackgroundTannenbaum, C., Martin, P., Tamblyn, R., Benedetti, A., & Ahmed, S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.949 · Cited by 665
“The median (range) number of participants per cluster was 10 (2-27).”
BackgroundBrandt, J., & Leong, C. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0207-7 · Cited by 356
“However, evidence has shown, with limited conflicting results and adherence to expected pharmacological principles, that the risk of falls and fractures increases with higher doses [51, 55, 58–60], use of interacting medications [55], and after treatment initiation, particularly during the first 1–2 weeks of drug expo…”
BackgroundResultGreenblatt, D. J., & Roth, T. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.667074 · Cited by 283
Potentially Harmful Drug–Drug Interactions in the Elderly: A Review
Hines, L. E., & Murphy, J. E. (2011) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.10.004 · Cited by 272
Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis
Donnelly, K., Bracchi, R., Hewitt, J., Routledge, P. A., & Carter, B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0174730 · Cited by 225
“However, Berry et al. 2013, Bakken et al. 2014, Chang et al. 2008 and Zint et al. 2010 suggested significant harm with even short-term prescriptions.”
BackgroundTrends in prescribing of sedative-hypnotic medications in the USA: 1993-2010.
Kaufmann, C. N., Spira, A. P., Alexander, G. C., Rutkow, L., & Mojtabai, R. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3951 · Cited by 105
Poly, T. N., Islam, M. M., Yang, H.-C., & Li, Y.-C. (. (2020) · Joint Bone Spine · doi:10.1016/j.jbspin.2019.11.003 · Cited by 53
Metadata
- Authors
- Zint, K., Haefeli, W. E., Glynn, R. J., Mogun, H., Avorn, J., & Stürmer, T.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2010-10-07
- Volume
- 19
- Issue
- 12
- Pages
- 1248-1255
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W1977350710
- Cited by
- 108
- References
- 6
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.